CD133-directed CAR T-cells for MLL Leukemia: On-target, Off-tumor Myeloablative Toxicity

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2019 Feb 20

PMID 30778134

Citations 27

Authors

Clara Bueno

Talia Velasco-Hernandez

Francisco Gutierrez-Aguera

Samanta Romina Zanetti

Matteo L Baroni

Diego Sanchez-Martinez

Oscar Molina

Adria Closa

Antonio Agraz-Doblas

Pedro Marin

Eduardo Eyras

Ignacio Varela

Pablo Menendez

Affiliations

Soon will be listed here.

Citing Articles

CAR-T-Cell Therapy Based on Immune Checkpoint Modulation in the Treatment of Hematologic Malignancies.

Su M, Zhang Z, Jiang P, Wang X, Tong X, Wu G Cell Transplant. 2024; 33:9636897241293964.

PMID: 39506457 PMC: 11693693. DOI: 10.1177/09636897241293964.

Aberrant stem cell and developmental programs in pediatric leukemia.

Ling R, Cross J, Roy A Front Cell Dev Biol. 2024; 12:1372899.

PMID: 38601080 PMC: 11004259. DOI: 10.3389/fcell.2024.1372899.

CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy.

Cui Y, Luo M, Gu C, He Y, Yao Y, Li P Biophys Rep. 2024; 9(5):279-297.

PMID: 38516299 PMC: 10951476. DOI: 10.52601/bpr.2023.230020.

Zr-labeled ImmunoPET targeting the cancer stem cell antigen CD133 using fully-human antibody constructs.

Wyszatko K, Janzen N, Silva L, Kwon L, Komal T, Ventura M EJNMMI Res. 2024; 14(1):29.

PMID: 38498285 PMC: 10948676. DOI: 10.1186/s13550-024-01091-9.

Inhibitory CARs fail to protect from immediate T cell cytotoxicity.

Funk M, Heller G, Waidhofer-Sollner P, Leitner J, Steinberger P Mol Ther. 2024; 32(4):982-999.

PMID: 38384128 PMC: 11163222. DOI: 10.1016/j.ymthe.2024.02.022.

References

Li D, Hu Y, Jin Z, Zhai Y, Tan Y, Sun Y . TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. Leukemia. 2018; 32(9):2012-2016. DOI: 10.1038/s41375-018-0212-z. View

Aldoss I, Bargou R, Nagorsen D, Friberg G, Baeuerle P, Forman S . Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors. Leukemia. 2016; 31(4):777-787. DOI: 10.1038/leu.2016.391. View

Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G . Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Mol Ther. 2017; 25(3):580-592. PMC: 5363196. DOI: 10.1016/j.ymthe.2017.01.011. View

Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam R, Marschalek R . Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood. 2015; 126(25):2676-85. PMC: 4683329. DOI: 10.1182/blood-2015-09-667378. View

Paulsson K, Lilljebjorn H, Biloglav A, Olsson L, Rissler M, Castor A . The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015; 47(6):672-6. DOI: 10.1038/ng.3301. View

Menendez P, Caballero M, Prosper F, Del Canizo M, Perez-Simon J, Mateos M . The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen. Transfusion. 2002; 42(9):1159-72. DOI: 10.1046/j.1537-2995.2002.00190.x. View

Ghorashian S, Amrolia P, Veys P . Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL. Exp Hematol. 2018; 66:5-16. DOI: 10.1016/j.exphem.2018.07.002. View

Kenderian S, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette J . CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015; 29(8):1637-47. PMC: 4644600. DOI: 10.1038/leu.2015.52. View

Gardner R, Wu D, Cherian S, Fang M, Hanafi L, Finney O . Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016; 127(20):2406-10. PMC: 4874221. DOI: 10.1182/blood-2015-08-665547. View

10.

Quek L, Otto G, Garnett C, Lhermitte L, Karamitros D, Stoilova B . Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J Exp Med. 2016; 213(8):1513-35. PMC: 4986529. DOI: 10.1084/jem.20151775. View

11.

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

12.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

13.

Agraz-Doblas A, Bueno C, Bashford-Rogers R, Roy A, Schneider P, Bardini M . Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. Haematologica. 2019; 104(6):1176-1188. PMC: 6545849. DOI: 10.3324/haematol.2018.206375. View

14.

Guenther M, Lawton L, Rozovskaia T, Frampton G, Levine S, L Volkert T . Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2009; 22(24):3403-8. PMC: 2607073. DOI: 10.1101/gad.1741408. View

15.

Weiland J, Pal D, Case M, Irving J, Ponthan F, Koschmieder S . BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance. Leukemia. 2016; 30(9):1920-3. PMC: 4950966. DOI: 10.1038/leu.2016.64. View

16.

Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O . Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014; 28(8):1596-605. DOI: 10.1038/leu.2014.62. View

17.

Yin A, Miraglia S, Zanjani E, Almeida-Porada G, Ogawa M, Leary A . AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1998; 90(12):5002-12. View

18.

Wuchter C, Ratei R, Spahn G, Schoch C, Harbott J, Schnittger S . Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica. 2001; 86(2):154-61. View

19.

Mak A, Nixon A, Moffat J . The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription. Cancer Res. 2012; 72(8):1929-34. DOI: 10.1158/0008-5472.CAN-11-3589. View